Ñî¹óåú´«Ã½Ò•îl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Ñî¹óåú´«Ã½Ò•îl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medical Marijuana
  • Medigap Premiums
  • Food Stamp Work Rules
  • Patients in ICE Custody
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Medical Marijuana
  • Medigap Premiums
  • Food Stamp Work Rules
  • Patients in ICE Custody
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jan 30 2020

Full Issue

What To Know About Purdue Pharma Legal Fight: Bankruptcy Negotiations, Kickback Schemes And Lawsuits, Oh My!

Reuters, which broke news Tuesday about an alleged kickback scheme possibly involving the OxyContin manufacturer, breaks down the current legal charges the company faces. News on the epidemic is on prescription guidelines and a lack of followup care for teens, as well.

OxyContin maker Purdue Pharma LP and its controlling Sackler family have been negotiating with cities, counties and states on a proposed settlement worth an estimated $10 billion to resolve more than 2,600 lawsuits alleging they helped fuel the U.S. opioid crisis. Those negotiations could be complicated by a Reuters report on Tuesday that Purdue is the unidentified company that was involved in an alleged kickback scheme aimed at improperly boosting prescriptions of opioid medications, though it was not charged with wrongdoing and has said it is cooperating with Justice Department investigations. (1/29)

Confusion and inconsistencies about the government's opioid prescribing guidelines are in the spotlight again in a sweeping new FDA letter to the Senate responding to questions about the agency’s handling of the opioid crisis. Democratic Sens. Maggie Hassan and Ed Markey said that the CDC, Defense Department and VA have warned against prescribing opioids at doses that exceed 90 mg morphine equivalent per day and asked if FDA is considering any action, including drug labeling changes, to reflect that warning. (Karlin-Smith, 1/30)

Teenagers who land in emergency rooms after overdosing on opioids can benefit from adults who connect them to resources and addiction services right away. But that often doesn’t happen, according to a study published earlier this month in JAMA Pediatrics. (Bowen, 1/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
More Morning Briefings
RSS Feeds
  • Ñî¹óåú´«Ã½Ò•îl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF